OncoMatch/Clinical Trials/NCT06007729
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Is NCT06007729 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HS-20093 for head and neck squamous cell carcinoma.
Treatment: HS-20093 — HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with head and neck squamous cell carcinoma and other solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Patients who have progressed on or intolerant to standard therapie
Cannot have received: B7-H3 targeted therapy
Previous or current treatment with B7-H3 targeted therapy
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ dysfunction [excluded]
Kidney function
No hepatorenal syndrome
Liver function
No hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis
Cardiac function
Evidence of cardiovascular risk; severe, uncontrolled or active cardiovascular diseases [excluded]
Inadequate bone marrow reserve or organ dysfunction [excluded]. Evidence of cardiovascular risk. Severe, uncontrolled or active cardiovascular diseases. Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify